Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance

Blood

Volumn 91, Issue 8, 1998, Pages 2961-2968

  King Underwood, L ^a   Pritchard Jones, K ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER GENETICS; CANCER REGRESSION; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; FEMALE; GENE MUTATION; HETEROZYGOSITY; HUMAN; LEUKEMOGENESIS; MALE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0032522974     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.8.2961.2961_2961_2968     Document Type: Article

References (43)

1. Reddy JC, Licht JD: The WT1 Wilms' tumor suppressor gene: How much do we really know? Biochim Biophys Acta 1287:1, 1996
2. Hastie ND: The genetics of Wilms' tumor - a case of disrupted development. Annu Rev Genet 28:523, 1994
3. Pritchard-Jones K, Fleming S, Davidson D, Bickmore W, Porteous D, Gosden C, Bard J, Buckler A, Pelletier J, Housman D, van Heyningen V, Hastie N: The candidate Wilms' tumour gene is involved in genitourinary development. Nature 346:194, 1990
4. Inoue K, Ogawa H, Sonoda Y, Kimura T, Sakabe H, Oka Y, Miyake S, Tamaki H, Oji Y, Yamagami T, Tatekawa T, Soma T, Kishimoto T, Sugiyama H: Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 89:1405, 1997
5. King-Underwood L, Renshaw J, Pritchard-Jones K: Mutations in the Wilms' tumor gene WT1 in leukemias. Blood 87:2171, 1996
6. Kreidberg JA, Sariola H, Loring JM, Maeda M, Pelletier J, Housman D, Jaenisch R: WT-1 is required for early kidney development. Cell 74:679, 1993
7. Pritchard-Jones K, King-Underwood L: The Wilms tumour gene WT1 in leukaemia. Leuk Lymphoma 27:207, 1997
8. Bruening W, Pelletier J: A non-AUG translational initiation event generates novel WT1 isoforms. J Biol Chem 271:8646, 1996
9. Caricasole A, Duarte A, Larsson SH, Hastie ND, Little M, Holmes G, Todorov I, Ward A: RNA binding by the Wilms tumor suppressor zinc finger proteins. Proc Natl Acad Sci USA 93:7562, 1996
10. Larsson SH, Charlieu JP, Miyagawa K, Engelkamp D, Rassoulzadegan M, Ross A, Cuzin F, van Heyningen V, Hastie ND: Subnuclear localization of WT1 in splicing or transcription factor domains is regulated by alternative splicing. Cell 81:391, 1995
11. Harrington MA, Konicek B, Song A, Xia XL, Fredericks WJ, Rauscher FJ III: Inhibition of colony-stimulating factor-1 promoter activity by the product of the Wilms' tumor locus. J Biol Chem 268:21271, 1993
12. Zhang X, Fraizer G, Saunders G: Two hematopoietic specific enhancers of the WT1 gene function in different cell lineages. Blood 86:748a, 1995 (abstr suppl 1)
13. Fraizer GC, Wu YJ, Hewitt SM, Maity T, Ton CC, Huff V, Saunders GF: Transcriptional regulation of the human Wilms' tumor gene (WT1). Cell type-specific enhancer and promiscuous promoter. J Biol Chem 269:8892, 1994
14. Renshaw J, King-Underwood L, Pritchard-Jones K: Differential splicing of exon 5 of the Wilms tumour (WT1) gene. Genes Chromosom Cancer 19:256, 1997
15. Little M, Wells C: A clinical overview of WT1 gene mutations. Hum Mutat 9:209, 1997
16. Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H, Kita K, Hiraoka A, Masaoka T, Nasu K, Kyo T, Dohy H, Nakauchi H, Ishidate T, Akiyama T, Kishimoto T: WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 84:3071, 1994
17. Pritchard-Jones K, Renshaw J, King-Underwood L: The Wilms tumour (WT1) gene is mutated in a secondary leukaemia in a WAGR patient. Hum Mol Genet 3:1633, 1994
18. Huff V, Jaffe N, Saunders GF, Strong LC, Villalba F, Ruteshouser EC: WT1 exon 1 deletion/insertion mutations in Wilms tumor patients, associated with di- and trinucleotide repeats and deletion hotspot consensus sequences. Am J Hum Genet 56:84, 1995
19. Lens D, DeSchouwer PJJC, Hamoudi RA, AbdulRauf M, Farahat N, Matutes E, Crook T, Dyer MJS, Catovsky D: p53 abnormalities in B-cell prolymphocytic leukemia. Blood 89:2015, 1997
20. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Soc 53:457, 1958
21. Algar E, Blackburn D, Kromykh T, Taylor G, Smith P: Mutation analysis of the WT1 gene in sporadic childhood leukaemia. Leukemia 11:110, 1997
22. Carapeti M, Goldman JM, Cross NC: Dominant-negative mutations of the Wilms' tumour predisposing gene (WT1) are infrequent in CML blast crisis and de novo acute leukaemia. Eur J Haematol 58:346, 1997
23. Haber DA, Timmers HT, Pelletier J, Sharp PA, Housman DE: A dominant mutation in the Wilms tumor gene WT1 cooperates with the viral oncogene E1 A in transformation of primary kidney cells. Proc Natl Acad Sci USA 89:6010, 1992
24. Little MH, Prosser J, Condie A, Smith PJ, van Heyningen V, Hastie ND: Zinc finger point mutations within the WT1 gene in Wilms tumor patients. Proc Natl Acad Sci USA 89:4791, 1992
25. Borel F, Barilla KC, Hamilton TB, Iskandar M, Romaniuk PJ: Effects of Denys-Drash syndrome point mutations on the DNA binding activity of the Wilms' tumor suppressor protein WT1. Biochemistry 35:12070, 1996
26. Little M, Holmes G, Bickmore W, van Heyningen V, Hastie N, Wainwright B: DNA binding capacity of the WT1 protein is abolished by Denys-Drash syndrome point mutations. Hum Mol Genet 4:351, 1995
27. Park S, Schalling M, Bernard A, Maheswaran S, Shipley GC, Roberts D, Fletcher J, Shipman R, Rheinwald J, Demetri G, Griffin J, Minden M, Housman DE, Haber DA: The Wilms tumour gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma. Nat Genet 4:415, 1993
28. Kent J, Coriat AM, Sharpe PT, Hastie ND, van Heyningen V: The evolution of WT1 sequence and expression pattern in the vertebrates. Oncogene 11:1781, 1995
29. Semba K, Saito Ueno R, Takayama G, Kondo M: cDNA cloning and its pronephros-specific expression of the Wilms' tumor suppressor gene, WT1, from Xenopus laevis. Gene 175:167, 1996
30. Gessler M, Konig A, Arden K, Grundy P, Orkin S, Sallan S, Peters C, Ruyle S, Mandell J, Li F, Cavenee W, Bruns G: Infrequent mutation of the WT1 gene in 77 Wilms' Tumors. Hum Mutat 3:212, 1994
31. Baird PN, Groves N, Haber DA, Housman DE, Cowell JK: Identification of mutations in the WT1 gene in tumours from patients with the WAGR syndrome. Oncogene 7:2141, 1992
32. Schumacher V, Schneider S, Figge A, Wildhardt G, Harms D, Schmidt D, Weirich A, Ludwig R, Royer-Pokora B: Correlation of germ-line mutations and two-hit inactivation of the WT1 gene with Wilms tumors of stromal-predominant histology. Proc Natl Acad Sci USA 94:3972, 1997
33. Englert C, Vidai M, Maheswaran S, Ge Y, Ezzell RM, Isselbacher KJ, Haber DA: Truncated WT1 mutants alter the subnuclear localization of the wild-type protein. Proc Natl Acad Sci USA 92:11960, 1995
34. Holmes G, Boterashvili S, English M, Wainwright B, Licht J, Little M: Two N-terminal self-association domains are required for the dominant negative transcriptional activity of WT1 Denys-Drash mutant proteins. Biochem Biophys Res Commun 233:723, 1997
35. Kikuchi H, Akasaka Y, Kurosawa Y, Yoneyama H, Kato S, Hata J: A critical mutation in both WT1 alleles is not sufficient to cause Wilms' tumor. FEBS Lett 360:26, 1995
36. Moss TJ, Strauss LC, Das L, Feig SA: Secondary leukemia following successful treatment of Wilms' tumor. Am J Pediatr Hematol Oncol 11:158, 1989
37. Bonnet D, Dick JE: Human acute myeloid leukemia is organised as a hierarchy that originates from a primitive hematopoietic cell. Nature Med 3:730, 1997
38. Kudoh T, Ishidate T, Nakamura T, Akiyama T: Constitutive expression of the Wilms tumor suppressor gene WT1 in F9 embryonal carcinoma cells induces apototic cell death in response to retinoic acid. Oncogene 13:1431, 1996
39. Murata Y, Kudoh T, Sugiyama H, Toyoshima K, Akiyama T: The Wilms tumor suppressor gene WT1 induces G1 arrest and apoptosis in myeloblastic leukemia M1 cells. FEBS Lett 409:41, 1997
40. Menke AL, Shvarts A, Riteco N, van Ham RC, van der Eb AJ, Jochemsen AG: Wilms' tumor 1-KTS isoforms induce p53-independent apoptosis that can be partially rescued by expression of the epidermal growth factor receptor or the insulin receptor. Cancer Res 57:1353, 1997
41. Yamagami T, Sugiyama H, Inoue K, Ogawa H, Tatekawa T, Hirata M, Kudoh T, Akiyama T, Murakami A, Maekawa T: Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: Implications for the involvement of WT1 in leukemogenesis. Blood 87:2878, 1996
42. Algar EM, Khromykh T, Smith SI, Blackburn DM, Bryson GJ, Smith PJ: A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines. Oncogene 12:1005, 1996
43. Hewitt SM, Fraizer GC, Wu YJ, Rauscher FJ, 3rd, Saunders GF: Differential function of Wilms' tumor gene WT1 splice isoforms in transcriptional regulation. J Biol Chem 271:8588, 1996